window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

IL-23 inhibitor

  • Drug approval,Gastroenterology,Pharmaceuticals and therapeutics,Regulatory Affairs

    SMC accepts guselkumab for Crohn’s disease and ulcerative colitis in NHS Scotland

    The Scottish Medicines Consortium (SMC) has accepted guselkumab for the [...]

    November 12, 2025
  • Clinical Development,Clinical Trials,Dermatology,Pharmaceuticals and therapeutics

    Icotrokinra shows superiority to deucravacitinib in first head-to-head Phase 3 trials for plaque psoriasis

    Johnson & Johnson has reported new data from the Phase [...]

    September 23, 2025
  • Biologics & Biosimilars,Chronic diseases,Pharmaceuticals and therapeutics,Regulatory Affairs

    NICE recommends Johnson & Johnson’s TREMFYA for Crohn’s disease and ulcerative colitis in the UK

    The National Institute for Health and Care Excellence (NICE) has [...]

    September 8, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top